Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Leases (2020 - 2025)

Bolt Biotherapeutics' Current Leases history spans 6 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Current Leases fell 4.39% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $2.7 million, down 4.39%, while the annual FY2024 figure was $2.3 million, 19.09% down from the prior year.
  • Current Leases for Q3 2025 was $2.7 million at Bolt Biotherapeutics, up from $2.6 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.0 million in Q2 2024 and bottomed at $1.6 million in Q1 2021.
  • The 5-year median for Current Leases is $2.5 million (2023), against an average of $2.5 million.
  • The largest annual shift saw Current Leases soared 66.62% in 2021 before it decreased 19.09% in 2024.
  • A 5-year view of Current Leases shows it stood at $2.5 million in 2021, then dropped by 4.4% to $2.4 million in 2022, then increased by 16.35% to $2.8 million in 2023, then decreased by 19.09% to $2.3 million in 2024, then rose by 19.95% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Current Leases are $2.7 million (Q3 2025), $2.6 million (Q2 2025), and $2.4 million (Q1 2025).